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Problem Definition
Transfusions provide benefit to many patients in 
many settings but may be complicated by transfusion 
reactions (TR). There are no evidence-based studies 
to support premedicating patients that have not 
previously experienced a TR(1). Premedication with 
acetaminophen and diphenhydramine are associated 
with potential risks and cost implications over 
time(2). Premedications may also mask the symptoms 
of TR such as a fever or itching/hives, preventing the 
identification of a more severe TR in a timely manner. 
Aims For Improvement
Our aim is to eliminate premedication prior to 
outpatient transfusions in patients without a prior 
transfusion reaction by 75% within 1 year.
Proposed Intervention
To eliminate premedications, we plan to: 
• Hang informational pamphlets in the OIC
• Create an in-service course for OIC staff detailing 
proper transfusion history documentation and 
disadvantages of premedications
• To ensure ongoing compliance, we can create a 
myJeffHub-Learning course that will be mandatory 
for new OIC staff as well as a required annual 
refresher
Measurement Strategy
We will track the transfusion episodes after 
educational material has been distributed at the 
infusion centers. For each episode, the patient’s chart 
will be reviewed for premedication orders, the 
provider who placed the order, and documentation of 
a previous TR. We may publish individual provider 
and team metrics to track progress and encourage 
compliance. 
We will follow progress every 3 months after 
implementation. If we do not achieve our expected 
results, we plan to identify the group(s) involved and 
aid in re-educating them. 
Implementation Plan
The faculty mentors for this project will be Dr. Julie 
Karp and Dr. Alexis Peedin. This project will be an 
interdisciplinary collaboration between Transfusion 
Medicine, Medical Oncology, and nursing education. 
Our upcoming Transfusion Medicine fellow, Dr. 
Yuanzheng (Andrew) Gao, will take the lead of this 
project as of July 1, 2020. We expect the 
implementation of this program to begin on July 1st 
and continue on an ongoing basis. 
We estimate a budget of no more than $2000 to:
• cover the expenses of educational material
• myJeffHub-Learning course creation
• refreshments for live courses
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Data Collection
We gathered transfusion data from our outpatient 
infusion centers (OIC): 925 Chestnut Street, the 
Bodine Center, and JHN Infusion Center. In 
December 2019, 96 unique patients were transfused 
blood products with a total of 205 transfusion 
episodes. Of the 96 patients transfused, 82 (85%) 
were given or offered premedications, of which only 
14 (17%) patients had a prior TR reported (figure 1). 
When reviewing individual transfusion episodes, we 
noted that during 161 (79%) of 205 transfusion 
episodes, patients were given or offered 
premedications (figure 2). If this trend were 
extrapolated over one year, more than 1000 patients 
are likely to be affected. 
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